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ABSTRACT
Introduction: The population of the world is aging. In 2010, an estimated 524 million people were aged
65 years or older presenting eight percent of the global population. By 2050, this number is expected to
10 nearly triple to approximately 1.5 billion, 16 percent of the world’s population. Although people are
living longer, the quality of their lives are often compromised due to ill-health.
Areas covered: Of the conditions which compromise health as we age, obesity is at the forefront. Over
half of the global older population were overweight or obese in 2010, significantly increasing the risk of
a range of metabolic diseases. Although, it is well recognised excessive calorie intake is a fundamental
15 driver of adipose tissue dysfunction, the relationship between obesity; intrinsic aging; and fat metabo-
lism is less understood. In this review we discuss the intersection between obesity, aging and the
factors which contribute to the dysregulation of whole-body fat metabolism.
Expert commentary: Being obese disrupts an array of physiological systems and there is significant
crosstalk among these. Moreover it is imperative to acknowledge the contribution intrinsic aging makes
20 to the dysregulation of these systems and the onset of disease.
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1. Introduction
The world population is aging [1,2]. However, despite the
dramatic rise in life expectancy, global health is on the decline.
Of the clinical problems whose prevalence is increasing, obe-
25 sity, a chronic condition which is underpinned by an imbal-
ance between energy ingested versus energy expended, is the
most pronounced. Globally, more than half a billion adults
aged 20 years and older are obese (BMI>30 kg/m2) worldwide
[3]. In 2014, 39% of the world’s adult population were over-
30 weight (BMI >25 kg/m2), with 13% classed as obese, a figure
which has more than doubled since 1980 [3]. This problem is
amplified when the data for England is considered. In England,
it has been estimated ~80% of males aged 55–64 years are
overweight/obese, while and ~70% of females aged between
35 55 between 64 years are overweight/obese (Figure 1), [4].
It is projected 2.8 million people die annually as a result of
being overweight or obese [3]. These fatalities are under-
pinned by the pathological footprint left by obesity,
characterized by clinical conditions, which are the direct or
40 indirect result of being overweight or obese. Such conditions
include hypertension [6], insulin resistance [7], cardiovascular
disease (CVD) [8], type-2 diabetes mellitus (T2DM) [9], rheu-
matoid arthritis [10], dementia [11], and certain cancers, for
example, breast [12], colorectal [13], esophageal [14], pancrea-
45 tic [15], and gastric [16]. A feature of many of the diseases
associated with obesity is the disruption of whole-body fatty
acid metabolism; a metabolic system which is intimately
coupled with adipose tissue function [17]. An elementary
summary of the biological mechanisms which regulate fat
50metabolism is presented in Figure 2. Briefly, ingested lipids
are packaged intestinally and released into the blood stream
as chylomicrons. Chylomicrons are hydrolyzed by lipoprotein
lipase (LPL), releasing free fatty acids (FFAs) into a fatty acid
pool. FFAs are removed from the pool by muscle and hepatic
55tissue, where they are either oxidized or re-esterified. Hepatic
triacylglycerides (TAGs) can be shuttled into the blood stream
as a constituent of very-low-density lipoproteins (VLDLs).
During periods of fasting, or as a result of sustained physical
activity (PA), hormone-sensitive lipase (HSL) is activated, and
60serves to mobilize FFAs by hydrolyzing TAG found in adipose
tissue [17]. Conversely during the fed state, adipose tissue fat
storage is stimulated and fat mobilization suppressed by insu-
lin. The activity of HSL is regulated by insulin, via an increase
or decrease in the extent of phosphorylation of HSL, depend-
65ing on the respective metabolic state. Clearly, the mechanisms
which regulate fat metabolism are interdependent, and subtle
alterations to them can disrupt fat metabolism. For instance,
adipose tissue is a key regulatory hub within fat metabolism
and many of the clinical manifestations associated with obe-
70sity are a direct consequence of the enlargement of and/or an
increase in the number of cells found in adipose tissue, which
is the result of excessive TAG deposition [18]. However, it is
important to recognize that despite this, metabolically healthy
obese individuals may not have these clinical manifesta-
75tions [19].
The anatomical remodeling of adipose tissue results in a
pathophysiology, characterized by the release of excess FFAs;
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a state induced as a result of enhanced lipolysis [20]. This
pernicious metabolic state is often associated with immune
80 system dysfunction and increased hormonal secretion. For
instance, T2DM is regularly accompanied by a rise in inflam-
matory markers in tandem with hyperinsulinemia [21]. Excess
calorie intake is a key driver of adipose tissue dysfunction and
concomitant metabolic dysregulation; however, intrinsic aging
85 also contributes significantly to the dysfunction of adipocytes
and lipid metabolism more broadly [22,23]. In this paper, we
will discuss the relationship between whole-body fat metabo-
lism and the aging process. Our aim is to emphasize the
contribution aging has to play in disrupting whole-body fat
90 metabolism homeostasis and the contribution this makes to
health in addition to obesity.
2. Dysregulation of fatty acid metabolism with age
During aging, body fat is redistributed from subcutaneous
stores to the muscles and viscera [24–27]. Redistribution of
95fat to visceral adipose tissue is associated with a concomitant
rise in plasma FFAs [28]. However, it must be stressed this
study was conducted on individuals of different ethnicities,
and therefore, there may be differences in adipose tissue
metabolic activity. This is pathophysiologically significant as
100obesity provokes the release of excess FFAs. High levels of
these fatty acids are the drivers of lipotoxicity, a condition
characterized by an increase in oxidative stress [29]. The
coupling of dysregulated plasma fatty acid metabolism and
oxidative stress is an important link connecting fat metabolism
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Figure 1. Adult population weight by age and gender. Weight category defined by BMI; underweight <18.5 kg/m2, normal weight 18.5–25 kg/m2, overweight
25–30 kg/m2, obese 30–40 kg/m2, morbidly obese <40 kg/m2. (Data from [5]).
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Figure 2. Overview of fatty acid metabolism. Abbreviations: FFA, free fatty acids; HSL, hormone sensitive lipase; LPL, lipoprotein lipase; TAG, triacylglycerol; VLDL,
very low density lipoprotein. Arrows represent flux or the action of an enzyme. The Greek symbol theta represents utilisation of the metabolite.
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105 to one of the main theories of biogerontology; the free radical
theory of aging. This theory proposes that the damage which
accumulates with time in a biological system is a result of
oxidative stress, and thus accounts for aging [30,31].
Therefore, an increase in FFAs due to age-related fat redistri-
110 bution could indirectly be a major contributor to the overall
rise in oxidative stress; a hallmark of aging [32]. Additionally,
lipid accumulation within skeletal muscle cells is correlated
with insulin resistance. Moreover, a change in the lipid com-
position of muscle tissue has been shown to have a significant
115 impact on fatty acid metabolism, although not all muscle
fibers interact with fatty acid metabolism in the same manner
[33]. For instance, certain studies have found that type 1
muscle fibers have an increased response to insulin when
compared to their less-sensitive type II counterparts [34].
120 Elevated plasma fatty acids also contribute to hypertrigly-
ceridemia by disrupting lipogenesis inhibiting the flux of TAG
from the blood stream. This could explain the association
between increasing age and the increase in plasma TAG
observed in both males and females [35]. Insulin resistance
125 also accompanies excess FFAs, and is likely to be induced by a
decrease in the activity of the insulin receptor. It has also been
proposed lipotoxic-induced oxidative stress could have a role
to play in this phenomenon, as demonstrated by a recent
experimental study exposing cultured human hepatocytes to
130 FA-activated oxidative stress [36]. In addition, this study found
that FA exposure stimulated the production of the prothrom-
botic marker, plasminogen activator inhibitor-1 (PAI-1). This is
not surprising, as increased inflammation is also a pathophy-
siological response to elevated FFAs. For instance, Pararasa
135 et al. (2016) reported fasting plasma saturated fatty acids
(SFAs), monounsaturated fatty acids (MUFAs), and polyunsatu-
rated fatty acids (PUFAs) were significantly higher in healthy
middle-aged men (aged 58 ± 6.1 years) compared with their
younger counterparts (aged 24 ± 3.8 years). Furthermore,
140proinflammatory cytokines tumor necrosis factor α (TNF-α)
and interleukin 6 (IL-6) were significantly elevated in these
middle-aged subjects, while the anti-inflammatory IL-10 was
reduced [28]. The next section will explore the relationship
between inflammation, aging, and fat metabolism in greater
145depth.
3. Inflammaging
Aging is associated with concomitant chronic low-grade sys-
temic inflammation. This phenomenon is referred to as inflam-
maging [37]. Inflammaging is considered a risk factor for both
150morbidity and mortality in older people [38], as it is thought
the rise in inflammatory markers, such as C-reactive protein
(CRP) and IL-6 are associated with physiological dysregulation
and the onset of age-related disease. Stepanova et al. (2015)
observed obesity was associated with age-related chronic dis-
155ease, with a trend for co-occurrence. Specifically, the authors
found obesity to be prevalent in 37% of individuals with one
age-related chronic disease and in 58% of individuals with two
or more age-related chronic diseases. Additionally, the preva-
lence of hypercholesterolemia increased from 24% in healthy
160controls, to 34 and 52% in individuals with one and two or
more chronic diseases, respectively [39].
Several markers of inflammation are associated with the
accumulation of visceral adipose tissue including, the
proinflammatory cytokines IL-6, TNF-α, TFG-β1, monocyte
165chemotactic protein-1 (MCP-1), iNOS, coagulation factors,
fibrinogen, PAI-1, and acute-phase proteins serum amyloid
A (SAA) and CRP [40–45]. These biomarkers have a broad
range of physiological roles in the promotion of inflamma-
tion (Figure 3). For example, MCP-1 induces the migration of
170monocytes to the area [46], while the proinflammatory
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Figure 3. Hormonal interactions with fatty acid metabolism. Abbreviations: ATGL, adipose triglyceride lipase; ATP, adenosine triphosphate; DAG, diacylglycerol; FAS,
fatty acid synthase; FFA, free fatty acids; GH, growth hormone; HSL, hormone sensitive lipase; LPL, lipoprotein lipase; MAG, monoacylglycerol; MDH, malate
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cytokine IFN-γ induces monocyte polarization to M1 macro-
phages [47]. This is accompanied by progressive lipid accu-
mulation and foam-like cell formation within the adipose
tissue [48]. An increased M1:M2 ratio inflammatory profile is
175 associated with the further release of proinflammatory cyto-
kines, TNF-α, IL-1β, IL-6, and IL-12, in addition to an increase
in the expression of pattern recognition receptors, such as
TLR [49]. Moreover, elevated mitochondrial superoxide gen-
eration, and significantly reduced plasma glutathione were
180 associated with this inflammatory profile [28]. The resulting
inflammation has been associated with the promotion of
insulin resistance, mitochondrial dysfunction, ROS accumula-
tion, and the pathogenesis of T2DM [50]. Additionally,
inflammation affects fatty acid metabolism in a variety of
185 ways. For example, Zhang et al. (2002) demonstrated TNF-α
promotes the lipolysis of TAG in human adipocytes via the
activation of mitogen-activated protein kinase (MEK) and
extracellular signal-related kinase (ERK) and elevation of
intracellular cAMP [51]. Moreover, TNF-α activation of the
190 MEK1/2-ERK1/2 pathway has been implicated in the phos-
phorylation and concomitant increase in activity of HSL,
stimulating lipolysis, contributing to increased hepatic pro-
duction of glucose [52]. In addition, TNF-α inhibits the
maturation of adipocytes by selectively activating TNF
195 receptor 1 [53].
Interestingly, it appears a bidirectional relationship exists
between fatty acid metabolism and the immune response, as
FFAs can modulate the inflammatory response. However, it is
important to note FFAs exert different effects on the inflam-
200 matory status. For example, Pararasa et al. (2016) demon-
strated elevated palmitic acid (C16:0) was related to an
increase in TNF-α and mitochondrial superoxide generation,
while high levels of the SFAs stearic acid (C18:0) and lignoceric
acid (C24:0) have been associated with reduced transforming
205 growth factor β1 (TGF-β1) levels [28]. Furthermore, the PUFA
punicic acid (C18:3 (n-5)) has been observed to ameliorate the
mitochondrial dysfunction and insulin resistance-associated
adipocyte TNF-α expression [54]. Importantly, inflammation
induced by aging and obesity can be ameliorated by diet
210 [55,56]. For example, Bashir et al. (2016) demonstrated fish
oil supplementation resulted in a reduction in adiposity
index, serum cholesterol, serum TAG, and insulin resistance
in obese insulin-resistant mice fed a high-fat diet. Moreover,
this supplementation resulted in a reduction in M1 phenotype
215 markers, while M2 phenotype markers increased in a dose-
dependent manner [57]. In addition, fish oil has been
observed to reduce a range of inflammatory-related genes in
humans, including the gene encoding for matrix metallopro-
tease MMP9, which plays an important role in macrophage
220 infiltration [34]. Gironés-Vilaplana et al. (2014) describe several
Latin-American fruits that exhibit good antioxidant capacities,
and α-glucosidase and pancreatic lipase inhibitory activities,
which could be utilized in the treatment of obesity and T2DM
[58]. Additionally, it has been demonstrated inflammation can
225 also be ameliorated by weight loss. For instance, Aron-
Wisnewsky et al. (2009) reported a 15% total body weight
loss 3-months post-bariatric surgery, resulted in a twofold
reduction in the M1:M2 ratio [59].
4. The endocrine system: age-related modulation
230and obesity
As outlined in Figure 4, the endocrine system has a significant
role to play in the regulation of fatty acid metabolism [60]. For
instance, hormones such as insulin and glucagon interact with
fatty acid metabolism to remove glucose from the plasma.
235Postprandial insulin secretion, not only induces the transpor-
tation of GLUT4 to the plasma membrane, but increases non-
esterified fatty acids (NEFA) synthesis in addition to inhibiting
lipolysis [61,62]. Conversely, glucagon stimulates the release of
glucose, decreases NEFA synthesis, and upregulates lipolysis
240to increase the concentration of plasma glucose [63]. These
straightforward examples provide an insight into how the
endocrine system intersects with these metabolic systems.
However, hormone production diminishes with age [64],
which has an inevitable impact on fatty acid metabolism. In
245this section, we will explore in detail some of the hormones
that are key regulators of fat metabolism and how they
change with age and obesity.
5. Glucagon and the regulation of acetyl CoA
carboxylase
250NEFA synthesis is hormonally regulated at the irreversible
conversion of acetyl CoA to malonyl CoA by acetyl CoA
carboxylase [44]. Glucagon perturbs NEFA synthesis by
phosphorylating acetyl CoA carboxylase by cAMP-depen-
dent protein kinase, which in turn inactivates the enzyme,
255while insulin activates enzyme activity by promoting its
dephosphorylation [65]. Additionally, it has been demon-
strated epinephrine downregulates acetyl CoA carboxylase
activity [65]. However, it has been found in isolated hepa-
tocytes from rats, the ability of glucagon to stimulate phos-
260phorylase activity and cAMP generation decreases with
increasing age [66].
6. Lipolysis: hormone-sensitive lipase and LPL
Langin et al. (2005) determined obesity induced a 60%
decline in HSL expression in differentiated human preadipo-
265cytes. This under-expression of HSL may contribute to the
defect in lipolysis often observed in obesity [67], For exam-
ple, insulin inhibits HSL, and hence lipolysis via the activa-
tion of cAMP phosphodiesterase; increased degradation of
cAMP; and inhibition of Camp-dependent protein kinase.
270Insulin may also inhibit HSL independently of cAMP via
the activation of protein phosphatase [68]. Conversely, glu-
cagon; epinephrine; and growth hormone (GH) enhance HSL
activity and lipolysis [69].
The hydrolysis of TAG to FFA and glycerol by LPL is influ-
275enced by insulin. LPL activity in adipose tissue is greatest fol-
lowing feeding, and lowest during fasting [70]; however, the
effect of hormonal interactions appears to be site dependent.
For instance, it has been demonstrated LPL activity is elevated
by insulin in human adipose tissue, while a decrease is observed
280in skeletal muscle [71,72]. Glucagon has been observed to
elevate LPL activity in rat myocardial tissue and human plasma
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[73,74], and decrease LPL activity in rat adipose tissue [75].
Additionally, Ricart-Jané et al. (2005) observed that chronic
stress reduced LPL activity in adipose tissue, while limb muscle,
285 myocardial, adrenal, plasma, and total LPL activity increased.
These findings suggest catecholamines also interact with LPL in
a site-specific manner [76]. GH has also been observed to
increase heart and skeletal muscle LPL activity [77]. Obesity
has been associated with the elevation of insulin and glucagon,
290 while epinephrine and GH have observed to decline [78–80].
Moreover, aging has been associated with significant reduction
in both peak day and night secretion of GH [81]. Furthermore,
Esler et al. (1995) reported aging is associated with a 40%
decline in epinephrine secretion. It is important to note the
295 concomitant 20% reduction in plasma epinephrine clearance
[82]. From the perspective of aging, the activity of LPL has been
reported to reduce by as much as 55–60% [83,84]. This could in
part be explained by the decline in PA with age, as Bey and
Hamilton describe physical inactivity has been observed to
300 decrease heparin releasable LPL activity by 90–95% in rats,
with ambulatory activity accounting for ~95%.of the variation
between muscle fibers [85].
7. The HPA axis
The hypothalamic-pituitary-adrenal (HPA) axis is affected by
305aging [86]. It has been shown the HPA axis becomes increas-
ingly hyperresponsive as a result of this metabolic change in
middle-aged women [87]. Moreover, Roelfsema et al. (2012)
observed that basal; pulsatile; and total ACTH secretion was
1.4, 1.6, and 1.5 times greater, respectively, in obese preme-
310nopausal women, when compared to their normal-weight
counterparts. However, despite this increase in ACTH secre-
tion, cortisol levels remained unaffected. This is thought to be
due to the significant decline in sensitivity to ACTH, in addi-
tion to a decrease in this hormone’s efficacy [88]. Although it
315has been repeatedly observed that plasma cortisol is not
elevated in obese individuals, there is a greater generation
of cortisol within the adipose tissue, in addition to a rise in
cortisol metabolite excretion [87–89]. This may be due to 11β-
hydroxysteroid dehydrogenase type 1 (11β-HSD1), a bidirec-
320tional enzyme, which acts as a reductase to convert cortisone
to cortisol, and as a hydrolase for the reverse reaction [90].
While obesity is related to impaired hepatic 11β-HSD1 activity,
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it has been demonstrated that a 5.5 kg/m2 increase in BMI
reflected a 65% increase in adipose 11β-HSD1 activity in
325 middle-aged females [87]. This increase in adipose 11β-HSD1
resulted in an elevated generation of cortisol within the adi-
pose tissue, which may play a role in the pathogenesis of
obesity and obesity-related disease.
In young healthy female humans, combined SFA, MUFA,
330 and PUFA lipid–heparin infusion inhibited ACTH and cortisol
secretion [91]. Another study demonstrated that by increasing
serum FFA, both ACTH and cortisol decreased initially, before
increasing after 120 min. Interestingly, the decline in ACTH
was more pronounced in anorexic subjects, while cortisol
335 levels were unaffected [92]. The profile of the FFA may be an
important factor in determining the response of the HPA axis,
as determined by Katoh et al. (2004), who demonstrated that
the SFAs butyric acid (C4); caprylic acid (C8); lauric acid (C12);
palmitic acid (C16); and stearic acid (C18) significantly reduced
340 the CRH-induced basal ACTH release, whereas the unsaturated
fatty acids oleic acid (C18:1); linoleic acid (C18:2); linolenic acid
(C18:3); and arachidonic acid (C20:4) significantly increased
CRH-induced basal ACTH release in primary cultured rat ante-
rior pituitary cells [93]. Interestingly, a bidirectional relation-
345 ship between the HPA axis and adipose tissue may exist. Arad
et al. (2015) found that elevated cortisol, due to ACTH injec-
tion, may result in the development of central obesity and
insulin resistance [94]. However, as this study was conducted
in vitro, and using cells from rodents, one needs to be cautious
350 when considering the implications of these findings for
humans. It has also been demonstrated that aging affects
the HPA axis. Basal morning concentrations of dehydroepian-
drosterone (DHEA), dehydroepiandrosterone sulfate (DS), and
androstenedione (A4) were significantly reduced in older
355 females aged 55–68 when compared to younger females
aged 20–35-years old, while cortisol levels were similar in
both groups. In addition, the decline in DHEA, A4, and DS
with overnight dexamethasone treatment was more pro-
nounced in the older group [95]. Intriguingly, it has been
360 found that DHEA replacement did not correct the alterations
in meal fat partitioning and post absorptive lipolysis asso-
ciated with aging, while testosterone only partially amelio-
rated these changes [96].
8. Adipocytokines: leptin and adiponectin
365 It has been observed that increased adiposity may lead to
elevated levels of the satiety hormone leptin [40]. Amouzou
et al. (2016) report leptin increased from 14.7 ng/ml in non-
obese controls to 44.6 and 44.7 ng/ml, respectively, in insulin-
sensitive and insulin-resistant obese postmenopausal women,
370 aged between 50 and 64-years old [97]. Interestingly, males
appear to be more sensitive to the effects of leptin, and
therefore exhibit lower concentrations compared with
females; with leptin concentration and leptin receptor inver-
sely correlated with serum testosterone [98]. The increase in
375 adiposity observed with age and the concomitant elevation in
leptin and leptin resistance, has been associated with
enhanced lipolysis, reduced β-oxidation of fatty acids in addi-
tion to a reduction in glucose tolerance [99]. Moreover, it has
been postulated that leptin resistance may contribute to the
380pathogenesis of CVD [100]. In contrast, the adipocytokine
adiponectin decreases as a result of being obese [40].
Adiponectin promotes glucose utilization and fatty acid oxida-
tion, and reduction of this adipocytokine is associated with
insulin resistance [101]. For example, Amouzou et al. (2016)
385reported a decrease in adiponectin from 17.4 ng/ml in non-
obese controls to 12.1 and 9.3 ng/ml in insulin-sensitive and
insulin-resistant obese postmenopausal women, respectively
[97]. Kim et al. (2015) suggest the inhibition of adiponectin
amongst the obese may be due to, obesity-induced
390proinflammatory cytokines inducing the hypermethylation of
compact chromatin structures in the adiponectin gene pro-
moter by the methyl transfer enzyme DNA methyltransferase 1
(DNMT1), impeding the expression of adiponectin [102].
Interestingly, inhibition of DNMT1 activity, or supplementation
395with adiponectin or adiponectin receptor ameliorated induced
insulin resistance [102–104].
9. Mathematical modeling of lipid metabolism
From our discussion of obesity, fatty acid metabolism, and its
interaction with aging, it is apparent this is a complex system
400with many interacting biological components. Therefore, study-
ing these interactions is challenging. In recent years, biological
research has benefited significantly from using mathematical
modeling to help improve our understanding of multifaceted
biological systems (reviewed in [105–108]). This approach pro-
405vides a flexible framework which enables hypothesis exploration
and enables the dynamics of a biological system to be pre-
dicted. Recently, we used mathematical modeling to explore
how aging impacts the biological mechanisms responsible for
the regulation of whole-body cholesterol metabolism [109–111],
410and to explore the impact of acute and chronic levels of cortisol
on brain aging [86]. This model could be extended to include
some of the interactions between fat metabolism and cortisol
regulation discussed in this paper. More specific to fatty acid
metabolism, we also developed a mathematical model of micro-
415tubule growth and shrinkage for differential actions of short-
chain fatty acids in the gut [112]. Other groups have also used
mathematical modeling as conduit for understanding adipose
tissue regulation. For instance, Kim et al. (2008) developed a
mathematical model of adipose tissue metabolism. The model
420was able to simulate physiological responses from the different
expression levels of lipases and found that during epinephrine
infusion, lipases are differentially activated, such that DAG
breakdown is approximately four times faster than triglyceride
breakdown [113].
42510. Conclusions
Experimental evidence firmly suggests the dysregulation of fat
metabolism plays a role in the development of metabolic
conditions such as CVD and T2DM. This dysregulation is at
least partly driven by the disruption of adipose tissue due to
430excess fat accumulation, as a result of excess calorie intake. In
addition, the aging process affects the biological mechanisms
and physiological systems responsible for the homeostatic
maintenance fat metabolism. It is important to consider the
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contribution of both diet and intrinsic aging when exploring
435 the metabolic complications that accompany obesity.
11. Expert commentary
The world population is aging, and with a rise in the global
population comes an increase in the prevalence of age-related
diseases. Many of these diseases, such as CVD and T2DM are
440 impacted significantly by the dysregulation of fat metabolism.
Overweight and obesity are central to the disruption of fat
metabolism, as it is the fundamental factor which provokes a
rise in plasma FFAs. Increased plasma FFAs coincide with a
plethora of metabolic changes which contribute to the patho-
445 physiology of obesity and the eventual onset of disease. The
aging process also disrupts the physiological systems and bio-
logical mechanisms responsible for the regulation of fat meta-
bolism. Specifically, there is significant overlap between the
immune aging/inflammaging and the disruption of fat metabo-
450 lism. Age-related hormonal changes also disrupt fat metabolism,
while there is a negative impact on endocrine systems, such as
the HPA axis as a result of overweight/obesity. It is also impor-
tant to acknowledge the increased level of cross talk between
physiological systems as a result of aging and how it impacts the
455 onset of disease. This is particularly relevant as the global popu-
lation continues to rise, as it is predicted the prevalence of
obesity will also increase across all age groups in many coun-
tries. Excess caloric intake, coupled with a demographic change
in favor of older people will pose a significant challenge to
460 healthcare in coming years. To date, public health strategies
have failed to curb the increase in obesity, thus it will require
innovative and imaginative initiatives to stem this global crises.
12. Five-year view
● There will continue to be an increase in life expectancy
465 ● There will be a concomitant rise in the prevalence of
obesity
● Public health strategies to deal with this crises remain to
be developed
● Healthcare systems will continue to see a rise in clinical
470 conditions associated with obesity
● It will be increasingly recognized that intrinsic aging
must be considered in addition to excess caloric intake
when investigating the pathophysiology of obesity
Key issues
● Globally the population of the world is aging
475 ● The prevalence of obesity is on the increase
● With an increase in obesity, there comes a increase in the
metabolic condition which are associated with the dysre-
gulation of fat metabolism
● Intrinsic aging also impacts fat metabolism
480 ● Disturbances to fat metabolism may be related to the aging
process as well as excess calorie intake
● There is a bidirectional relationship between fatty acid
metabolism and inflammation
● Accumulation of visceral adipose tissue with age is asso-
485ciated with inflammation.
● Dysfunction of the endocrine system significantly impacts
fatty acid metabolism.
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